Keyphrases
Cancer Pathways
16%
Ciclopirox
16%
Clinical Samples
16%
Deferiprone
16%
Delayed Diagnosis
16%
Deoxyhypusine Hydroxylase
100%
Differentially Expressed
100%
Differentially Expressed Genes
16%
Differentially Expressed Proteins
16%
Drug Resistance
16%
Epithelial-mesenchymal Transition
16%
Eukaryotic Translation Initiation Factor 5A (eIF5A)
16%
Glioblastoma
100%
Glioblastoma Cells
33%
Glioblastoma Prognosis
16%
High-level Expression
16%
Hypusine
16%
Immunohistochemistry
16%
Invasive Phenotype
16%
Long-term Survivors
100%
Mass Spectrometry Analysis
16%
Molecular Markers
16%
Mouse Model
16%
Neoplasms
16%
Novel Therapeutic Targets
100%
Overexpression
16%
Patient Outcomes
16%
Poor Prognosis
16%
Proliferation Inhibition
16%
Proliferation Migration
16%
Prolonged Survival
16%
Proteogenomics
16%
Proteomic Analysis
16%
Quantitative PCR
16%
Related Pathway
16%
RNA Sequencing (RNA-seq)
16%
Short Hairpin RNA (shRNA)
16%
Small Fraction
16%
Small Molecules
16%
Survival Rate
16%
Survivors
16%
Therapeutic Use
16%
Tumor Aggressiveness
16%
Tumor Drugs
16%
Tumor Growth
16%
Tumor Heterogeneity
16%
Tumor Invasiveness
16%
Tumor Progression
16%
Unnatural Amino Acids
16%
Pharmacology, Toxicology and Pharmaceutical Science
Ciclopirox
12%
Deferiprone
12%
Deoxyhypusine
100%
Drug Resistance
12%
Essential Amino Acid
12%
Glioblastoma
100%
Hypusine
12%
Initiation Factor 5A
12%
Malignant Neoplasm
12%
Molecular Marker
12%
Mouse Model
12%
Neoplasm
37%
Oxygenase
100%
Short Hairpin RNA
12%
Survival Rate
12%
Tumor Growth
25%
Biochemistry, Genetics and Molecular Biology
Anabolism
16%
Drug Resistance
16%
Essential Amino Acid
16%
Eukaryotic Translation
16%
Genetic Marker
16%
Initiation Factor
16%
Mass Spectrometry
16%
Mesenchymal-Epithelial Transition
16%
Mouse Model
16%
Oxygenase
100%
Proteogenomics
16%
Proteomics
16%
Real-Time Polymerase Chain Reaction
16%
RNA Sequencing
16%
Small Hairpin RNA
16%
Small Molecule
16%
Survival Rate
16%
Tumor Progression
33%